Schering Intron A hepatitis B pediatric supplement filed Sept. 2.
Executive Summary
SCHERING INTRON A PEDIATRIC SUPPLEMENT submitted Sept. 2 seeks an indication for the recombinant interferon alfa-2b product for the treatment of hepatitis B in patients one to 17 years of age. The supplemental BLA is based on Phase IV study data, Schering-Plough says. Intron A is currently marketed for adults as a treatment for hepatitis B, chronic hepatitis C, malignant melanoma and hairy cell leukemia.